Exploring Three High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks requires a focus on companies with strong innovation potential and robust financial health that can capitalize on long-term trends despite short-term fluctuations.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Five9, Inc. offers intelligent cloud software solutions for contact centers globally and has a market capitalization of approximately $1.10 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, totaling $1.15 billion.

Five9’s strategic alliance with Aspect, enhancing real-time customer engagement through advanced forecasting and workforce optimization, underscores its commitment to leveraging AI and cloud technologies for operational efficiency. This partnership is poised to drive significant value by integrating historical and live interaction data into workforce management platforms, optimizing staffing needs against customer demand fluctuations. With a robust annual revenue growth of 8.2% and an impressive turnaround to a net income of $39.42 million from a previous year’s loss, Five9 demonstrates solid financial improvement. Moreover, the company’s R&D focus remains strong as it collaborates with tech giants like Google Cloud to innovate in enterprise customer experience solutions, ensuring it stays at the forefront of the high-demand cloud-based contact center market.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America, with a market cap of approximately $1.49 billion.

Operations: Vericel generates revenue primarily from its biotechnology segment, amounting to $276.26 million. The company operates in the sports medicine and severe burn care markets across North America.

Vericel has demonstrated robust growth with a 59.4% increase in earnings over the past year, outpacing the biotech industry’s 40.2% average, signaling strong operational performance and market acceptance. This growth trajectory is supported by significant R&D investments aimed at expanding its product lines and enhancing existing offerings. Recently, FDA approval for commercial manufacturing of MACI at its new facility marks a strategic milestone, enabling increased capacity and potential international expansion. With anticipated revenue growth of 14.7% annually and earnings expected to surge by 32.7% per year, Vericel is strategically positioned to capitalize on advanced therapies in cartilage repair amidst growing global demand.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company that focuses on discovering, developing, manufacturing, and commercializing genetic medicines to address diseases with high unmet medical needs in the United States, with a market cap of approximately $7.17 billion.

Operations: Krystal Biotech focuses on genetic medicines, generating $389.13 million in revenue from treating diseases with high unmet medical needs in the U.S.

Krystal Biotech’s recent achievements and strategic milestones underscore its robust position in the biotech sector. In 2025, the company reported a substantial increase in net income to $204.83 million, up from $89.16 million the previous year, highlighting a remarkable earnings growth of 129.7%. This performance is bolstered by significant R&D investments which have facilitated innovations like KB707 for NSCLC treatment, receiving FDA’s RMAT designation for accelerated development pathways. With revenue and earnings forecasted to grow annually at 24.3% and 28.9% respectively, Krystal is well-positioned to leverage advanced gene therapies addressing critical medical needs.

Taking Advantage

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com